Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone Unaudited Financial Results For The Quarter and half year Ended On 30Th September, 2026.

Ref. No.: JPL/CS/2369/2026. Date : 29th October, 2026. BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street,Fort, Mumbai - 400 001. Script Code :524731 Sub. : Board Meeting. Reg.: Intimation under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. Dear Sir, In continuation to our letter No. JPL/CS/2353/2026 dated 22nd September, 2026, kindly note that with reference to the captioned regulation, a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 3rd November, 2026, at the Registered Office of the Company, inter-alia, to take on record the standalone unaudited financial results for the quarter and half year ended on 30th September, 2026. Kindly take on record the above. Thanking you, Yours faithfully, For Jenburkt Pharmaceuticals Limited, ASHISH SHAH Sr. Vice President & Company Secretary.